LMO1 overexpression is a new predictive marker for anti‐EGFR therapy.23, 24 However, no significant differences were observed for LMO1 gene expression level between tumour tissues and corresponding adjacent benign tissues in human breast cancer, hepatocellular carcinoma (HCC) and gastric cancer (GC), which suggests that LMO1 gene may display a more complex functional network in these cancers.24 Sun et al25 have found that the expression levels of LMO1 in gastric cancer tissues were higher than those in adjacent tissues and the overexpression of LMO1 could be as a markers of poor prognosis. The gene discussed is LMO1; the disease is hepatocellular carcinoma.